Лечение инфекций мочеполовой системы: настоящее и будущее

Введение Инфекции мочеполовой системы (ИМС) относятся к наиболее распространенным инфекционным заболеваням, приводящим к значительным финансовым затратам.

Реферат подготовлен В.В. Иремашвили по материалам статьи F.M.E. Wagenlehner, K.G. Naber «Treatment of Bacterial Urinary Tract Infections: Presence and Future», European Urology 2006; 49: 235–244.

Литература 1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelone¬phritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29(4):745–58. 2. Foxman B. Epidemiology of urinary tract infections: inci¬dence, morbidity, and economic costs. Am J Med 2002; 113(Suppl. 1A):5S–13S. 3. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J Urol 2002;168(4 Pt 2):1720–2. 4. Gales AC, Jones RN, Gordon KA, et al. Activity and spec¬trum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Chemother 2000;45(3):295–303. 5. Ruden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community–acquired infections in Ger¬many. Summary of the results of the First National Pre¬valence Study (NIDEP). Infection 1997;25(4):199–202. 6. Maki DG, Tambyah PA. Engineering out the risk for infec¬tion with urinary catheters. Emerg Infect Dis 2001; 7(2):342–7. 7. Patton JP, Nash DB, Abrutyn E. Urinary tract infection: economic considerations. Med Clin North Am 1991; 75(2):495–513. 8. Lai KK, Fontecchio SA. Use of silver–hydrogel urinary catheters on the incidence of catheter–associated urinary tract infections in hospitalized patients. Am J Infect Con¬trol 2002;30(4):221–5. 9. Naber KG. Which ?uoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001;17(4):331–41. 10. Wagenlehner F, Naber KG. Antibiotics and resistance of uropathogens. EAU Update Series 2004;2:125–35. 11. Abraham E, Chain E. An encyme from bacteria able to destroy penicillin. Nature 1940;146:837. 12. Bauer H, Ble?mann GS, Pitrow DB, Rahlfs VW. Prevention of recurrent urinary tract infections with immunoactive E. coli fractions. Eur J Obstet Gyn 1999;86:33. 13. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Pre¬vention of recurrent urinary tract infections with immuno–active E. coli fractions: a meta–analysis of ?ve placebo–controlled double–blind studies. Int J Antimicrob Agents 2002;19(6):451–6. 14. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC. A long–term, multicenter, double–blind study of an Escherichia coli extract (OM–89) in female patients with recurrent urinary tract infections. Eur Urol 2005;47(4):542–8, discussion 548. 15. Albert X, Huertas I, Pereiro II, Sanfelix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non–pregnant women. Cochrane Data¬base Syst Rev (3):2004. p. CD001209. 16. Riedasch G, Mo?hring K. Immunisierungstherapie rezidi¬vierender Harnwegsinfekte der Frau. Therapiewoche 1986;6:896–900. 17. Reid G, Bruce RW. Probiotics to prevent urinary tract infec¬tions: the rationale and evidence. World J Urol in press. 18. Reid G, Bruce AW, Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol Ther 1995;23:32–45. 19. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactoba¬cillus rhamnosus GR–1 and L. fermentum RC–14 signi?¬cantly alters vaginal ?ora: randomized, placebo–controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003;35(2):131–4. 20. Fraga M, Scavone P, Zunino P. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infec¬tion in a mouse model. Antonie Van Leeuwenhoek 2005;88(1):25–34. 21. Fischetti VA. Bacteriophage lytic enzymes: novel anti¬infectives. Trends Microbiol 2005;13(10):491–6. 22. Cheng Q, Nelson D, Zhu S, Fischetti VA. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005;49(1):111–7. 23. Yoong P, Schuch R, Nelson D, Fischetti VA. Identi?cation of a broadly active phage lytic enzyme with lethal activity against antibiotic–resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol 2004;186(14):4808–12. 24. Langermann S, Mollby R, Burlein JE, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000;181(2):774–8. 25. Meiland R, Geerlings SE, Langermann S, Brouwer EC, Coenjaerts FE, Hoepelman AI. Fimch antiserum inhibits the adherence of Escherichia coli to cells collected by voided urine specimens of diabetic women. J Urol 2004;171(4):1589–93. 26. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Lever–son GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol 2003;170(3):867–9. 27. Li X, Mobley HL. Vaccines for Proteus mirabilis in urinary tract infection. Int J Antimicrob Agents 2002;19(6):461–5. 28. Zhao X, Drlica K. Restricting the selection of antibiotic–resistant mutants: a general strategy derived from ?uor¬oquinolone studies. Clin Infect Dis 2001;33(Suppl. 3): S147–56. 29. Drlica K. Antibiotic resistance: can we beat the bugs? Drug Discov Today 2001;6(14):714–5. 30. Sano M, Takahashi S, Nishimura M, et al. A clinical study on combination therapy of antimicrobial agents for com¬plicated urinary tract infection–with special reference to combination with clarithromycin. Nippon Hinyokika Gakkai Zasshi 1997;88(6):596–604. 31. Vogel F, Naber KG, Wacha H, Shah P, So?rgel F, Kayser FH, et al. Parenterale Antibiotika bei Erwachsenen. Che¬motherapie J 1999;8:2–49. 32. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative In vitro activities of daptomycin and vancomycin against resistant gram–positive pathogens. Antimicrob Agents Chemother 2000;44(12):3447–50. 33. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Che¬mother 2003;47(8):2682–4. 34. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Che¬mother 2002;49(3):467–70. 35. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45(3):845–51. 36. Woodworth JR, Nyhart Jr EH, Brier GL, Wolny JD, Black HR. Single–dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36(2):318–25. 37. De Bruin MF, Tally FP. Ef?cacy and safety of daptomycin for the treatment of bacteremia and serious infections due to Gram–positive bacteria. in 4th Decennial International Conference on Nosocomial and Healthcare–Associated Infec¬tions, 2000 Vol. Abstract 594, 2000. 38. Rubinstein E, Vaughan D. Tigecycline: a novel glycylcy¬cline. Drugs 2005;65(10):1317–36. 39. Kumamoto Y, Tsukamoto T, Matsukawa M, et al. Com¬parative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). I. Susceptibility distribu¬tion. Jpn J Antibiot 2004;57(3):246–74. 40. Heinzl S. Neue Antibiotika Chemotherapie Journal 2005;14:54–7. 41. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram–negative bacilli with various beta–lactamase resis¬tance mechanisms. Diagn Microbiol Infect Dis 2005; 52(1):71–4. 42. Henry Jr DC, Bettis RB, Riffer E, et al. Comparison of once–daily extended–release cipro?oxacin and conventional twice–daily cipro?oxacin for the treatment of uncompli¬cated urinary tract infection in women. Clin Ther 2002;24(12):2088–104. 43. Wagenlehner FM, Kinzig–Schippers M, Tischmeyer U, Wagenlehner C, Sorgel F, Dalhoff A, Naber KG. Pharma¬cokinetics of cipro?oxacin XR (1000 mg) versus volunteers receiving a single oral dose. Int J Antimicrob Agents 2005;Dec 9, [Epub ahead of print]. 44. Talan DA, Naber KG, Palou J, Elkharrat D. Extended–release cipro?oxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents 2004;23(Suppl. 1):S54–66. 45. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001;47(Suppl. 3):3–8, discussion 44–48. 46. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Micro¬biol Infect Dis 2003;22(4):203–21. 47. Eschenburg S, Priestman MA, Abdul–Latif FA, Dela¬chaume C, Fassy F, Schonbrunn E. A novel inhibitor that suspends the induced ?t mechanism of UDP–N–acetylglu¬cosamine enolpyruvyl transferase (MurA). J Biol Chem 2005;280(14):14070–5. 48. Kaatz GW. Inhibition of bacterial ef?ux pumps: a new strategy to combat increasing antimicrobial agent resis¬tance. Expert Opin Emerg Drugs 2002;7(2):223–33. 49. Heinisch L, Wittmann S, Stoiber T, Scherlitz–Hofmann I, Ankel–Fuchs D, Mollmann U. Synthesis and biological activity of tris–and tetrakiscatecholate siderophores based on poly–aza alkanoic acids or alkylbenzoic acids and their conjugates with beta–lactam antibiotics. Arz¬neimittelforschung 2003;53(3):188–95. 50. Neu HC. The crisis in antibiotic resistance. Science 1992;257(5073):1064–73.